The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients.
Disturbances of lipid metabolism are frequently encountered after renal transplantation and have been ascribed to the use of cyclosporine (CsA) and corticosteroids, but the individual contribution of each of these drugs remains uncertain. The individual effects of CsA and prednisone (Pred) on serum lipid and (apo)lipoprotein levels were compared in a prospective randomized trial. All patients received CsA and Pred during the first 3 months after transplantation. Subsequently, they were allocated to either withdrawal of Pred or conversion from CsA to azathioprine (Aza). Serum lipids and (apo)lipoproteins, including lipoprotein(a) (Lp(a)), were measured at regular intervals during the first year after renal transplantation. Analysis of variance for repeated measures of the first year results showed higher values for serum triglycerides (P < 0.001) and lower high-density lipoprotein (HDL) cholesterol levels (P < 0.05) in the CsA monotherapy group (N = 59) as compared with the AzaPred group (N = 63). At 1 yr after transplantation, CsA-treated patients had significantly higher Lp(a) levels (CsA: median, 105 (interquartile range 42 to 340) mg/L; Aza-Pred: 46 (25 to 176) mg/L; P < 0.05). The withdrawal of Pred in the CsA group resulted in a large fall in HDL cholesterol (27 +/- 30% at 5 months after transplantation) and an increase in triglycerides (49 +/- 73% at 6 months). A reversion of these changes was observed in patients who were retreated with Pred. Multiple linear regression analysis showed an independent correlation between the use of Pred and HDL cholesterol level, whereas the use of CsA was independently associated with the concentration of Lp(a).(ABSTRACT TRUNCATED AT 250 WORDS)
Hilbrands
L B
LB
Department of Medicine, University Hospital Nijmegen, The Netherlands.
Demacker
P N
PN
Hoitsma
A J
AJ
Stalenhoef
A F
AF
Koene
R A
RA
D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D001161:Arteriosclerosis / Q000453:epidemiology / Q000517:prevention & control*; D001379:Azathioprine / Q000494:pharmacology / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D006973:Hypertension / Q000097:blood / Q000150:complications; D007674:Kidney Diseases / Q000150:complications / Q000601:surgery; D016030:Kidney Transplantation; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications; D011183:Postoperative Complications / Q000517:prevention & control*; D011241:Prednisone / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011446:Prospective Studies; D011507:Proteinuria / Q000097:blood / Q000150:complications; D012306:Risk; D012307:Risk Factors
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008055:Lipids; D008074:Lipoproteins; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone